UK Plans Upfront Payment Scheme To Spur Antimicrobial Development
A new UK project will look at the potential of upfront payments to encourage companies to invest in the development of new antimicrobial drugs. The scheme, developed by NICE and NHS England, will use a tailored health technology assessment approach and is seen as a possible model for other countries to emulate in the fight against antimicrobial resistance.
You may also be interested in...
A novel Swedish payment scheme and transferable exclusivity vouchers for new antimicrobials are among mechanisms being examined by the European Commission for encouraging the development of new drugs to tackle the growing problem of antibiotic resistance.
The UK pharma industry association has underscored the sector’s importance while outlining its demands for the country’s policy around medicines and R&D.
Despite the life sciences industry’s call for continued alignment of medicines regulation with the EU from next year and for some sort of co-operation with the European Medicines Agency, it seems the UK government is prepared to make only small concessions.